Biotech returning to favor
Biotech returning to favor “After a nearly four-year slowdown, money is beginning to flow again into the biotechnology sector. But it’s more a trickle than a torrent. “
Biotech returning to favor “After a nearly four-year slowdown, money is beginning to flow again into the biotechnology sector. But it’s more a trickle than a torrent. “
Drug firms in United States, Europe move biotech work to India “Drug makers in the United States and Europe are increasingly moving clinical trials and research work to India, which helped Indian firms earn US$54 million in revenue in the last fiscal year…”
Singapore Wants You! “The future-friendly city-state has an offer bioscientists can’t refuse: unrestricted research, top-notch equipment, and limitless funds. (Just leave your chewing gum at home.)”
Biotech’s Longer Convalescence “The biotech sector has fallen, and it doesn’t seem able to get up. “
Biotech’s Longer Convalescence “The biotech sector has fallen, and it doesn’t seem able to get up. “
China: how to seize “commanding point” of biotechnology “China’s capital investment in the scientific research of life science is far from enough, and the government should create fine environment for the development of biotechnology industry, and mobilize all forces in the society to develop biotechnology and industry…”
China: how to seize “commanding point” of biotechnology “China’s capital investment in the scientific research of life science is far from enough, and the government should create fine environment for the development of biotechnology industry, and mobilize all forces in the society to develop biotechnology and industry…”
Stem-Cell Cash on a Winding Road They may not be investing in the companies themselves, but venture capitalists haven’t completely abandoned stem-cell work. Instead, they’re contributing through efforts like the California Stem Cell Initiative…
Financial Snapshot For June 2004 Lackluster Performance
ImClone Hammered as Sales Lag Estimates Scandal-plagued ImClone Systems may have fallen off the road to recovery. While the company’s second-quarter earnings beat Wall Street estimates, the stock plunged yesterday on disappointing sales of the company’s key cancer drug.